SUPERNUS PHARMACEUTI...
Display and export data
General & Ratios
Financial Statements
/
In the 'original' view, the statements are displayed just as they are being reported by the company.
In the 'standardised' view, the statements are displayed in a standardised format (line items are identical for all companies).
Add data
Click on one of the orange fields in the profile to add new information
Edit or review data
Legend (for Financial Statements)
Passed value check (?)
Failed value check (?)
Click on a coloured field in the profile to review the data
Close sidebar
Loading: 100%
SUPERNUS PHARMACEUTICALS INC logo
no logo available
General Information
Investor relations pageIR page no data available
Founding year no data available
Headquarter , , no data available
Employees (as per )no data available
Sector Drug Manufacturers, HealthcareDrug Manufacturers, Healthcareno data available
Ticker SUPNno data available
Financial year endsFY ends End of no data available
Stock Information (historical prices adjusted for splits and dividends)
Adj. Closing prices (in USD) -Common sharesNov. 16Jan. 17März 17Mai 17Juli 17Sep. 17015304560
datesClosing price (adj.)
13.10.201741.35
11.10.201741.20
04.10.201741.35
27.09.201739.05
20.09.201736.75
13.09.201747.90
06.09.201746.75
30.08.201743.55
23.08.201745.00
16.08.201745.65
09.08.201741.20
02.08.201740.60
26.07.201742.20
19.07.201743.55
12.07.201744.40
05.07.201742.75
27.06.201741.85
20.06.201741.40
13.06.201738.60
06.06.201739.65
30.05.201735.40
23.05.201734.55
16.05.201733.55
09.05.201732.90
02.05.201733.25
25.04.201732.95
18.04.201731.85
11.04.201731.18
04.04.201730.90
28.03.201730.85
21.03.201728.45
14.03.201727.35
07.03.201726.40
28.02.201725.70
21.02.201725.85
14.02.201726.40
07.02.201724.65
31.01.201727.05
24.01.201724.88
17.01.201723.80
10.01.201726.10
03.01.201725.95
27.12.201625.70
19.12.201625.65
12.12.201623.20
05.12.201622.20
28.11.201621.65
21.11.201622.25
14.11.201623.90
07.11.201618.70
31.10.201619.80
24.10.201620.65
17.10.201620.69
no share price data source found
Share price data requested
Key Figures
Last Closing Price
as per Oct 13, 2017, in USD
 41.35n/a
Market Capitalisation
in million USD
 2,079n/a
Enterprise Value
in million USD
 1,995n/a
Common Shares Outstanding
as per May 2, 2017
 50,282,397n/a
Preferred Shares Outstanding
as per May 2, 2017
 49,000,000n/a
Average Basic Shares Outstanding
TTM
 49,702,068n/a
Average Diluted Shares Outstanding
TTM
 52,112,076n/a
Index Membership
n/a
Business Summary
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders.
no data available
Key Financials & Ratios (all figures TTM as per , million USD, full statements further below)
Profit & Loss
Revenues 0n/a
Gross Profit 0n/a
Operating Income 0n/a
EBITDA 0n/a
Net Profit 0n/a
Balance Sheet
Cash and Cash Equivalents 87n/a
Receivables 39n/a
Total Current Assets 150n/a
PP&E 4n/a
Total Assets 322n/a
Accounts Payable 5n/a
Current Debt 0n/a
Total Current Liabilities 82n/a
Long-Term Debt 3n/a
Total Liabilities 116n/a
Total Equity 206n/a
Cash Flow
Depreciation & Amortisation 0n/a
Change in Working Capital 0n/a
Operating Cash Flow 0n/a
Net Change in PP&E and Intangibles 0n/a
Investing Cash Flow 0n/a
Dividends Paid 0n/a
Financing Cash Flow 0n/a
Total Change in Cash 0n/a
Free Cash Flow 0n/a
Profitability Ratios
Gross Margin 0.0%n/a
Operating Margin 0.0%n/a
Net Profit Margin 0.0%n/a
Return on Equity 0.0%n/a
Return on Assets 0.0%n/a
Per Share Figures
Basic EPS n/a
Diluted EPS n/a
Sales per Share n/a
Book Value per Share n/a
FCF per Share n/a
Dividends per Share n/a
Price Multiples
Price to Earnings Ratio n/a
Price to Sales Ratio n/a
Price to Book Value n/a
Price to Free Cash Flow n/a
Valuation Metrics
EV/EBITDA n/a
EV/Sales n/a
Book to Market Value 0.10n/a
Other Ratios
Current Ratio 182.6%n/a
Liabilities to Equity Ratio 56.4%n/a
Debt to Assets Ratio 1.0%n/a
Profit & Loss StatementP&L data quality: 0% (?)
edit
No data available yet
Loading data...
No data available for the original financial statements for the selected time periods. You can change the selected time periods by clicking on 'data' on the top right.
Standardised statements can't be displayed.
Reason:
No data available for the selected time periods
in million USD FY '10FY '11FY '12FY '13FY '14FY '15FY '16
Revenue
0
1
1
12
93
147
215
Sales & Services Revenue
0
0
0
0
0
0
0
Financing Revenue
0
0
0
0
0
0
0
Other Revenue
0
0
0
0
0
0
0
Cost of revenue
0
0
0
-1
-6
-8
-12
Cost of Goods & Services
0
0
0
0
0
0
0
Cost of Financing Revenue
0
0
0
0
0
0
0
Cost of Other Revenue
0
0
0
0
0
0
0
Gross Profit
0
1
1
11
87
139
203
Other Operating Income
0
0
0
0
0
0
0
Operating Expenses
-40
-39
-44
-73
-92
-118
-149
Selling, General & Administrative
-5
-8
-20
-56
-73
-89
-106
Selling & Marketing
0
0
0
0
0
0
0
General & Administrative
0
0
0
0
0
0
0
Research & Development
-35
-31
-24
-17
-20
-29
-43
Depreciation & Amortization
0
0
0
0
0
0
0
Provision For Doubtful Accounts
0
0
0
0
0
0
0
Other Operating Expense
0
0
0
0
0
0
0
Operating Income (Loss)
-40
-38
-42
-62
-5
21
54
Non-Operating Income (Loss)
0
2
4
8
6
5
7
Interest Expense, net
0
2
4
8
6
5
7
Interest Expense
0
0
0
0
0
0
0
Interest Income
0
0
0
0
0
0
0
Other Investment Income (Loss)
0
0
0
0
0
0
0
Foreign Exchange Gain (Loss)
0
0
0
0
0
0
0
Income (Loss) from Affiliates
0
0
0
0
0
0
0
Other Non-Operating Income (Loss)
-1
0
0
0
0
0
0
Pretax Income (Loss), Adjusted
-41
-36
-39
-54
1
26
61
Abnormal Gains (Losses)
0
0
1
23
0
2
0
Acquired In-Process R&D
0
0
0
0
0
0
0
Merger / Acquisition Expense
0
0
0
0
0
0
0
Abnormal Derivatives
0
0
0
0
0
0
0
Disposal of Assets
0
0
0
0
0
0
0
Early extinguishment of Debt
0
0
0
0
0
0
0
Asset Write-Down
0
0
0
0
0
0
0
Impairment of Goodwill & Intangibles
0
0
0
0
0
0
0
Sale of Business
0
0
0
0
0
0
0
Legal Settlement
0
0
0
0
0
0
0
Restructuring Charges
0
0
0
0
0
0
0
Sale of and Unrealized Investments
0
0
0
0
0
0
0
Insurance Settlement
0
0
0
0
0
0
0
Other Abnormal Items
0
0
0
0
0
0
0
Pretax Income (Loss)
-41
-36
-38
-31
0
28
61
Income Tax (Expense) Benefit, net
0
16
0
0
-1
-1
41
Current Income Tax
0
0
0
0
0
0
0
Deferred Income Tax
0
0
0
0
0
0
0
Tax Allowance/Credit
0
0
0
0
0
0
0
Income (Loss) from Affiliates, net of taxes
0
0
0
0
0
0
0
Income (Loss) from Continuing Operations
-40
-20
-38
-31
0
28
102
Net Extraordinary Gains (Losses)
0
0
0
0
0
0
0
Discontinued Operations
0
0
0
0
0
0
0
XO & Accounting Charges & Other
0
0
0
0
0
0
0
Income (Loss) Including Minority Interest
-40
-20
-38
-31
0
28
102
Minority Interest
0
0
0
0
0
0
0
Net Income
-40
-20
-38
-31
0
28
102
Preferred Dividends
-3
-3
-1
0
0
0
0
Other Adjustments
0
0
0
0
0
0
0
Net Income Available to Common Shareholders
-44
-23
-39
-31
0
28
102
Remarks
restated on Mar 15, 2013 n/a
calculated values,
restated on Mar 21, 2014 n/a
calculated values,
restated on Mar 12, 2015 n/a
calculated values,
restated on Jan 20, 2017 n/a
calculated values,
restated on Mar 16, 2017 n/a
calculated values,
restated on Mar 16, 2017 n/a
calculated values,
restated on Mar 16, 2017 n/a
calculated values,
Balance SheetBS data quality: 100% (?)
edit
No data available yet
Loading data...
No data available for the original financial statements for the selected time periods. You can change the selected time periods by clicking on 'data' on the top right.
Standardised statements can't be displayed.
Reason:
No data available for the selected time periods
in million USD FY '10FY '11FY '12FY '13FY '14FY '15FY '16
Assets
Cash, Cash Equivalents & Short Term Investments
n/a
49
89
82
74
62
90
Cash & Cash Equivalents
n/a
49
40
33
36
33
66
Short Term Investments
n/a
0
48
49
38
29
24
Accounts & Notes Receivable
n/a
0
0
5
17
26
42
Accounts Receivable, Net
n/a
0
0
5
17
26
42
Notes Receivable, Net
n/a
0
0
0
0
0
0
Unbilled Revenues
n/a
0
0
0
0
0
0
Inventories
n/a
0
1
7
13
13
17
Raw Materials
n/a
0
0
0
0
0
0
Work In Process
n/a
0
0
0
0
0
0
Finished Goods
n/a
0
0
0
0
0
0
Other Inventory
n/a
0
0
0
0
0
0
Other Short Term Assets
n/a
1
2
3
4
5
3
Prepaid Expenses
n/a
0
1
3
4
5
3
Derivative & Hedging Assets
n/a
0
0
0
0
0
0
Assets Held-for-Sale
n/a
0
0
0
0
0
0
Deferred Tax Assets
n/a
0
0
0
0
0
0
Income Taxes Receivable
n/a
0
0
0
0
0
0
Discontinued Operations
n/a
0
0
0
0
0
0
Miscellaneous Short Term Assets
n/a
0
1
0
0
0
0
Total Current Assets
n/a
49
91
97
109
106
151
Property, Plant & Equipment, Net
n/a
1
1
3
2
4
4
Property, Plant & Equipment
n/a
0
0
0
0
0
0
Accumulated Depreciation
n/a
0
0
0
0
0
0
Long Term Investments & Receivables
n/a
0
0
9
20
55
75
Long Term Investments
n/a
0
0
0
0
0
0
Long Term Marketable Securities
n/a
0
0
0
0
0
0
Long Term Receivables
n/a
0
0
0
0
0
0
Other Long Term Assets
n/a
3
1
3
6
24
78
Intangible Assets
n/a
1
1
1
0
1
16
Goodwill
n/a
0
0
0
0
0
0
Other Intangible Assets
n/a
0
0
0
0
0
0
Prepaid Expense
n/a
0
0
0
0
0
0
Deferred Tax Assets
n/a
0
0
0
0
0
42
Derivative & Hedging Assets
n/a
0
0
0
0
0
0
Prepaid Pension Costs
n/a
0
0
0
0
0
0
Discontinued Operations
n/a
0
0
0
0
0
0
Investments in Affiliates
n/a
0
0
0
0
0
0
Miscellaneous Long Term Assets
n/a
2
0
1
6
23
20
Total Noncurrent Assets
n/a
4
3
14
28
83
158
Total Assets
n/a
54
94
111
137
189
310
Liabilities and owners' equity
Payables & Accruals
n/a
12 11763000
11 10666000
18 18314000
28 27980000
56 56261000
77 77432000
Accounts Payable
n/a
0 0
0 0
3 3142000
2 1863000
4 4314000
8 8055000
Accrued Taxes
n/a
0 0
0 0
0 0
0 0
0 0
0 7000
Interest & Dividends Payable
n/a
0 0
0 0
0 0
0 0
0 0
0 0
Other Payables & Accruals
n/a
12 11763000
11 10666000
15 15172000
26 26117000
52 51947000
69 69370000
Short Term Debt
n/a
7 6775000
12 11809000
0 0
0 0
0 0
0 0
Short Term Borrowings
n/a
0 0
0 0
0 0
0 0
0 0
0 0
Short Term Capital Leases
n/a
0 0
0 0
0 0
0 0
0 0
0 0
Current Portion of Long Term Debt
n/a
0 0
0 0
0 0
0 0
0 0
0 0
Other Short Term Liabilities
n/a
0 232000
1 508000
8 8086000
0 143000
1 673000
3 3310000
Deferred Revenue
n/a
0 232000
1 508000
0 204000
0 143000
0 176000
0 209000
Derivatives & Hedging
n/a
0 0
0 0
0 0
0 0
0 0
0 0
Deferred Tax Liabilities
n/a
0 0
0 0
0 0
0 0
0 0
0 0
Discontinued Operations
n/a
0 0
0 0
0 0
0 0
0 0
0 0
Miscellaneous Short Term Liabilities
n/a
0 0
0 0
8 7882000
0 0
0 497000
3 3101000
Total Current Liabilities
n/a
19 18770000
23 22983000
26 26400000
28 28123000
57 56934000
81 80742000
Long Term Debt
n/a
23 22711000
11 11088000
34 34393000
26 26223000
7 7085000
4 4165000
Long Term Borrowings
n/a
0 0
0 0
0 0
0 0
0 0
0 0
Long Term Capital Leases
n/a
0 0
0 0
0 0
0 0
0 0
0 0
Other Long Term Liabilities
n/a
3 2806000
2 2348000
17 16738000
42 41739000
37 36600000
33 32906000
Accrued Liabilities
n/a
0 0
0 0
0 0
0 0
0 0
0 0
Pension Liabilities
n/a
0 245000
0 0
0 0
0 0
0 0
0 0
Pensions
n/a
0 245000
0 0
0 0
0 0
0 0
0 0
Other Post-Retirement Benefits
n/a
0 0
0 0
0 0
0 0
0 0
0 0
Deferred Compensation
n/a
0 0
0 0
0 0
0 0
0 0
0 0
Deferred Revenue
n/a
0 465000
0 309000
1 1417000
1 1274000
1 1390000
2 1501000
Deferred Tax Liabilities
n/a
0 0
0 0
0 0
0 0
0 0
0 0
Derivatives & Hedging
n/a
1 697000
0 251000
13 12644000
7 6564000
1 854000
0 114000
Discontinued Operations
n/a
0 0
0 0
0 0
0 0
0 0
0 0
Miscellaneous Long Term Liabilities
n/a
1 1399000
2 1788000
3 2677000
34 33901000
34 34356000
31 31291000
Total Noncurrent Liabilities
n/a
26 25517000
13 13436000
51 51131000
68 67962000
44 43685000
37 37071000
Total Liabilities
n/a
44 44287000
36 36419000
78 77531000
96 96085000
101 100619000
118 117813000
Preferred Equity
n/a
0 49000
0 0
0 0
0 0
0 0
0 0
Share Capital & Additional Paid-In Capital
n/a
49 49364000
144 143882000
212 211992000
230 230306000
264 264004000
276 276177000
Common Stock
n/a
0 0
0 0
0 0
0 0
0 0
0 0
Additional Paid in Capital
n/a
0 0
0 0
0 0
0 0
0 0
0 0
Other Share Capital
n/a
0 0
0 0
0 0
0 0
0 0
0 0
Treasury Stock
n/a
0 0
0 0
0 0
0 0
0 0
0 0
Retained Earnings
n/a
-40 -39971000
-86 -86255000
-179 -178528000
-189 -189453000
-176 -175509000
-84 -84288000
Other Equity
n/a
0 1000
0 -57000
0 0
0 -154000
0 -488000
0 -134000
Equity Before Minority Interest
n/a
9 9443000
58 57570000
33 33464000
41 40699000
88 88007000
192 191755000
Minority Interest
n/a
0 0
0 0
0 0
0 0
0 0
0 0
Total Equity
n/a
9 9443000
58 57570000
33 33464000
41 40699000
88 88007000
192 191755000
Total Liabilities & Equity
n/a
54 53730000
94 93989000
111 110995000
137 136784000
189 188626000
310 309568000
Remarks restated on n/a restated on Mar 15, 2013 n/a restated on Mar 21, 2014 n/a restated on Mar 12, 2015 n/a restated on Jan 20, 2017 n/a restated on Mar 16, 2017 n/a restated on May 9, 2017 n/a
Cash Flow StatementCF data quality: 0% (?)
edit
No data available yet
Loading data...
No data available for the original financial statements for the selected time periods. You can change the selected time periods by clicking on 'data' on the top right.
Standardised statements can't be displayed.
Reason:
No data available for the selected time periods
in million USD FY '10FY '11FY '12FY '13FY '14FY '15FY '16
Net Income/Starting Line
-39
-23
-46
-92
-11
14
91
Net Income
0
0
0
0
0
0
0
Net Income From Discontinued Operations
0
0
0
0
0
0
0
Other Adjustments
0
0
0
0
0
0
0
Depreciation & Amortization
1
1
1
1
1
1
2
Non-Cash Items
0
-16
1
28
5
7
-35
Stock-Based Compensation
0
0
0
0
0
0
0
Deferred Income Taxes
0
0
0
0
0
0
0
Other Non-Cash Adjustments
0
0
0
0
0
0
0
Change in Working Capital
6
-1
-3
4
-20
12
9
(Increase) Decrease in Accounts Receivable
0
0
0
0
0
0
0
(Increase) Decrease in Inventories
0
0
0
0
0
0
0
Increase (Decrease) in Accounts Payable
0
0
0
0
0
0
0
Increase (Decrease) in Other
0
0
0
0
0
0
0
Net Cash From Discontinued Operations (operating)
0
0
0
0
0
0
0
Cash from Operating Activities
-32
-39
-47
-59
-25
34
67
Change in Fixed Assets & Intangibles
0
-1
-1
-2
-3
-13
-20
Disposition of Fixed Assets & Intangibles
0
0
0
0
0
0
0
Disposition of Fixed Assets
0
0
0
0
0
0
0
Disposition of Intangible Assets
0
0
0
0
0
0
0
Acquisition of Fixed Assets & Intangibles
0
0
0
0
0
0
0
Purchase of Fixed Assets
0
0
0
0
0
0
0
Acquisition of Intangible Assets
0
0
0
0
0
0
0
Other Change in Fixed Assets & Intangibles
0
0
0
0
0
0
0
Net Change in Long Term Investment
26
9
-48
-10
0
-26
-16
Decrease in Long Term Investment
0
0
0
0
0
0
0
Increase in Long Term Investment
0
0
0
0
0
0
0
Net Cash From Acquisitions & Divestitures
0
0
0
0
0
0
0
Net Cash from Divestitures
0
0
0
0
0
0
0
Cash for Acqusition of Subsidiaries
0
0
0
0
0
0
0
Cash for Joint Ventures
0
0
0
0
0
0
0
Net Cash from Other Acquisitions
0
0
0
0
0
0
0
Other Investing Activities
0
0
0
0
0
0
0
Net Cash From Discontinued Operations (investing)
0
0
0
0
0
0
0
Cash from Investing Activities
26
8
-49
-12
-3
-39
-36
Dividends Paid
0
0
0
0
0
0
0
Cash From (Repayment of) Debt
0
30
-7
64
0
0
0
Cash From (Repayment of) Short Term Debt, net
0
0
0
0
0
0
0
Cash From (Repayment of) Long Term Debt, net
0
0
0
0
0
0
0
Repayments of Long Term Debt
0
0
0
0
0
0
0
Cash From Long Term Debt
0
0
0
0
0
0
0
Cash From (Repurchase of) Equity
0
0
101
2
1
2
2
Increase in Capital Stock
0
0
101
2
1
2
2
Decrease in Capital Stock
0
0
0
0
0
0
0
Other Financing Activities
-1
-1
-6
-4
30
0
0
Net Cash From Discontinued Operations (financing)
0
0
0
0
0
0
0
Cash from Financing Activities
-1
29
88
63
31
2
2
Net Cash Before Disc. Operations and FX
-8
-2
-8
-9
2
-4
33
Change in Cash from Disc. Operations and Other
0
0
0
0
0
0
0
Net Cash Before FX
-8
-2
-8
-9
2
-4
33
Effect of Foreign Exchange Rates
0
0
0
0
0
0
0
Net Changes in Cash
-8
-2
-8
-9
2
-4
33
Remarks
restated on Mar 15, 2013 n/a
calculated values,
restated on Mar 21, 2014 n/a
calculated values,
restated on Mar 12, 2015 n/a
calculated values,
restated on Jan 20, 2017 n/a
calculated values,
restated on Mar 16, 2017 n/a
calculated values,
restated on Mar 16, 2017 n/a
calculated values,
restated on Mar 16, 2017 n/a
calculated values,
Some of the data shown on this page is provided for free by IEX
About | Contact Forum | Legal
SimFin UG 2017 - Beta v. 1.42
Facebook | Twitter | Medium
Sumo